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Primary thymic adenocarcinoma is a very rare malignancy of the anterior mediastinum with no standardized treatment. 
A 36-year-old male patient presented with hoarseness over the past 3 months. A chest computed tomography (CT) scan 
showed an infiltrative mass to the proximal vessels and aortic arch in left upper mediastinum (4.1×3.1×5.4 cm). Brain 
magnetic resonance imaging (MRI) showed focal lesions, suggesting metastasis in the left frontal lobe. A thoracoscopic 
biopsy of the mediastinal mass confirmed a primary thymic adenocarcinoma forming a glandular structure with atypia 
of tumor cells. The patient received four cycles of systemic chemotherapy, consisting of etoposide and cisplatin, with 
concurrent radiotherapy (6,000 cGy/30 fractions) to the mediastinal lesion and the metastatic brain lesion (4,200 cGy/12 
fractions). A follow-up chest CT scan and brain MRI showed a decrease in the size of the left upper mediastinal mass and 
brain lesion. We report a rare case of the primary thymic adenocarcinoma with a literature review.
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Thymic carcinoma originated from thymic epithelium with 
a high degree of histological anaplasia, cell atypia, paucity of 
lymphocytes, and increased proliferation2. Most common 
subtypes of thymic carcinoma based on their histological dif-
ferentiation is keratinizing/non-keratinizing squamous cell 
carcinoma (76%) followed by basaloid type (3%)3. Neuroen-
docrine, mucoepidermoid, lymphoepithelioma-like, sarco-
matoid, clear cell, papillary and anaplastic subgroups are also 
reported4. Among those subtypes of thymic carcinoma, pri-
mary thymic adenocarcinoma is a very rare subtype of thymic 
carcinoma. Subtypes of primary thymic adenocarcinoma are 
listed below; mucinous, papillotubular, conventional, papil-
lary, and not otherwise specific (NOS)5. 
More than half of the thymic carcinoma showed overex-
pression of c-kit , a type III tyrosine kinase receptor protein 
encoded by the proto-oncogene kit which regulates cell pro-
liferation, differentiation, adhesion and apoptosis (50%–80%) 
while thymoma rarely presented c-kit  expression (0%–5%)6. 
Malignant transformation of benign epithelial cells of thymic 
cyst is necessary for making a diagnosis of the primary thymic 
adenocarcinoma. Clear-cut atypia of tumor epithelial cells 
with the severity typical of carcinoma with exclusions of car-
cinoids, metastasis to the thymus, germ cell tumor, and mes-
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Introduction
In Korea, there were 492 cases of malignancies in the medi-
astinum in 20111. The incidence of thymic carcinoma is less 
than 50 per year. Among the thymic carcinoma, only three 
cases of primary thymic adenocarcinoma have been reported 
in Korea for now.
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enchymal tumors with epithelial features are major criteria of 
the thymic carcinoma7. Immunohistochemical (IHC) staining 
of CD5 (leukocyte marker expressed on differentiating thymo-
cytes) is useful in differentiating thymic from non-thymic car-
cinomas8. Negative IHC results in thyroid transcription factor 
1 (TTF1) and calretinin are also important to exclude those 
tumors derived from the lung and pleura from the primary 
thymic adenocarcinoma5. 
For the diagnosis of the primary thymic adenocarcinoma, 
radiologic findings confirming the anterior mediastinal mass 
with no evidence of primary tumor in other organs and patho-
logic diagnosis based on hematoxylin and eosin (H&E) stain-
ing and IHC staining are required. 
For the clnical presentation of the thymic carcinoma, the 
most common symptoms are chest pain, shortness of breath, 
cough, hoarseness of the voice, dysphagia those derived by 
pressure effect of the mass4. About 41% of the patients with 
thymic adenocarcinoma nearly present any symptoms5. 
Because of the rareness of the cases, standard treatment 
for the primary thymic adenocarcinoma has not been estab-
lished so far resulted in poor clinical outcomes. For the more 
information about the primary thymic adenocarcinoma, we 
underwent literature review of the almost all previously pub-
lished case reports and small case series in our knowledge ex-
cept one case written in Chinese which will be discussed later. 
We report a case of rare primary thymic adenocarcinoma 
which is carried out in accordance with the Declaration of 
Helsinki and Korean Good Clinical Practice (GCP) guidelines 
with the informed consent of the patient. The review of the 
study is approved by the respective Institutional Review Board 
(IRB) of the Gangnam Severance Hospital (IRB No. 3-2014-
0194).
Case Report
A 36-year-old man presented with hoarseness for 3 months 
and infiltrative mass in the left upper mediastinum on neck 
computed tomography (CT) scan. He visited our hospital via 
local otolaryngology-head and neck surgery clinic after the 
diagnosis of upper respiratory tract infection treated with cold 
medicine for a while. The patient presented no medical his-
tory except a 23 pack-year smoking history. On the physical 
examination, neither engorged neck vein nor palpable neck 
nodes were observed.
Initial chest CT scan (Figure 1A) showed an infiltrative mass 
in the left upper mediastinum (4.1×3.1×5.4 cm), encircling the 
left common carotid artery and left subclavian artery. Brain 
magnetic resonance imaging (MRI) with contrast (Figure 2B) 
revealed focal enhancing lesion in the left frontal lobe suggest-
ing metastasis. Torso positron emission tomography (PET)/
CT presented about 1.6-cm hypermetabolic lesion in left para-
vertebral region of thoracic spine two (T2) level and 3.9-cm-
sized hypermetabolic mass in the left upper mediastinal 
region just above the aortic arch which seems the same lesion 
observed with chest CT. Those radiologic imaging study were 
suggestive small cell lung cancer. Elevated plasma levels of 
carcinoembryonic antigen (CEA) and neuron specific enolase 
(NSE) were also supportive evidence for suggesting small cell 
lung cancer (CEA, 6.0 ng/mL [0.2–5.0 ng/mL]; NSE, 12.9 ng/
mL [7.5–12.5 ng/mL]). However, thoracoscopic biopsy of the 
mediastinal mass showed unexpected results at all; presence 
of carcinoma suggestive of adenocarcinoma was reported. 
To conclude this finding, multiple mediastinoscopic biopsies 
of the left upper mediastinal side of the infiltrative mass and 
lymph nodes around the mass were performed. Pathologic 
results showed an adenomatous feature with glandular for-
mation and immunoreactive for cytokeratin, CEA, and CD5 
(Figure 2A, B) which means this tumor is adenocarcinoma 
originated from the thymus. IHC staining for TTF1 and napsin 
A (Figure 2C) were negative and was able to exclude tumors 
derived from the lung. The patient diagnosed as primary thy-
mic adenocarcinoma (conventional subtype) and staged as 
Masaoka stage IV. A complete resection was not performed 
due to the invasion of the proximal vessel and aortic arch.  
After the pathologic diagnosis has confirmed, the patient 
underwent four cycles of chemotherapy composed of 120 
mg/m2 etoposide for D1–3 and 60 mg/m2 cisplatin for a D1 
A B
Figure 1. Radiographic images before 
treatment. (A) Chest computed tomog-
raphy scan shows an infiltrative mass to 
the proximal vessel and aortic arch in 
the left upper mediastinum measured 
4.1×3.1×5.4 cm, encircling the left com-
mon carotid artery and left subclavian 
artery. (B) Brain magnetic resonance 
imaging with contrast revealed focal 
enhancing lesion in the left frontal lobe 
suggesting metastasis.
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every 3 weeks. Concomitant radiation therapy (6,000 cGy/30 
fractions; Tomo-Helical, TomoTherapy, Wisconsin MI, USA) 
to the lesion followed by salvage radiotherapy to the meta-
static brain lesion (4,200 cGy/12 fractions; Tomo-Helical) and 
mediastinum (3,000 cGy/12 fractions; Tomo-Helical) were 
also administrated. The patient completed the planned treat-
ment without other complications. 
Chest CT scan performed at a 1-month follow-up visit (Fig-
ure 3A) revealed decreased mass size (4.1 cm to 2.8 cm in 
diameter) and 3-month follow-up chest CT (Figure 3B) pre-
sented stable disease status described as no interval change of 
residual encasing solid mass lesion at the left superior medi-
astinum near the proximal neck vessel and aortic arch. Brain 
MRI performed at a 1-month follow-up visit (Figure 3C) and 
3-month follow-up visit (Figure 3D) presented decreased focal 
lesion on left frontal lobe area. PET-CT taken at 1-month fol-
low up visit showed disappeared hypermetabolic mass lesion 
just above the aortic arch, nearly disappeared hypermetabolic 
nodes in left supraclavicular region and markedly decreased 
fluoro-2-deoxyglucose uptake in the shrunken lesion of left 
paravertebral region, second thoracic spine level which are 
considered favorable response to the treatment. Regular chest 
CT follow-up in 3 months is planned.
Discussion
Primary thymic adenocarcinoma is an extremely rare dis-
ease especially in female. Since the first case report from the 
japan in 1989 by Moriyama et al. (Table 1, case No. 1)5, twenty-
seven cases of primary thymic adenocarcinoma have been re-
ported. Literature review on primary thymic adenocarcinoma 
is shown in Tables 1 and 2. In Table 1, we analyzed a total of 28 
cases including our case to the literally reviewed data. Patient 
range in age was from 15 to 82 years and the median age was 
51 years. Twenty out of 28 was male and male:female ratio is 
C
A B
Figure 2. Histopathological findings of the thymic tumor for the diag-
nosis of primary thymic adenocarcinoma. (A) H&E staining showed 
an infiltrative tumor forming an adenomatous structure with atypia 
of tumor epithelial cells in mediastinal lymph nodes and medias-
tinal mass using light microscopy (×200). Immunohistochemical 
staining revealed CD5, thymus cell marker, positive in this tumor (B) 
and negative finding of alveolar cell marker TTF-1 and Napsin A (C) 
(B and C, ×400). Taken together, these tumors were adenocarcino-
mas originating from the thymus.
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2.5:1. 
Fifteen out of 28 patients were immunoreactive for CD5 
which is a leukocyte marker expressed during a differentiation 
of thymocyte. Nine out of 28 were not available to find out a 
record for IHC staining of CD5. Sixteen out of 28 were tested 
for TTF1 and presented negative value which means those 
lesions are not come from the lung adenocarcimona. Except 
our case, only one case reported in 2004 underwent Napsin A 
IHC staining and presented negative value (Table 1, case No. 
9). 
There were variable lesions except the primary mediastinal 
tumor; pleura, pericardium, aortic arch, mediastinal lymph 
node, sternum, lung, and extrathoracic lesion like liver, kid-
neys, and brain. 
For the clinicopathological analysis described in Table 2, 
12 patients presented thymic mucinous adenocarcinoma ac-
counting the most common subtype of the thymic adenocar-
cinoma followed by papillary carcinoma presented in eight 
patients. Three out of 28 showed papillotubular adenocarci-
noma. Three out of 28 were conventional and 2 out of 28 were 
classified NOS. Male patients tended to present more lesions 
except the primary mediastinal tumor than female cases (male 
vs. female is 9 out of 20 vs. 2 out of 8) (Table 2). 
Most primary thymic adenocarcinoma cases reported to 
date were operable as noted in Table 1. Those cases under-
went operation followed by postoperative radiotherapy alone 
or postoperative chemotherapy plus radiotherapy to the 
resected lesion. So far, the outcomes of primary thymic ad-
enocarcinoma treated with resection of the tumor followed by 
radiotherapy alone were not successful. Bone metastasis at 18 
months (Table 1, case No. 6) and retroperitoneal lymph node 
metastasis at 5 months (Table 1, case No. 14) were reported in 
those cases. Postoperative chemotherapy plus radiation ther-
apy expected to favorable outcomes—but most of the cases 
revealed metastasis and death of disease at 11 to 26 months 
(Table 1, case Nos. 8, 13, 17, 18, 19, 26). Although there was 
one 41-year-old man case presented no evidence of disease 
at 43 months after diagnosis got radiotherapy to the primary 
thymic mucinous adenocarcinoma lesion followed by resec-
tion both of the primary thymic adenocarcinoma (10.5×8.0×2.5 
cm) and metastatic lung lesion with adjuvant radiotherapy 
and chemotherapy (Table 1, case No. 12), one 82-year-old fe-
male case passed away from the complication of surgery after 
resection of 14.5×7.0-cm-sized mass (Table 1, case No. 15).
Comparing with other cases, we described a 36-year-old 
male patient presenting inoperable primary thymic adeno-
carcinoma with infiltration to the proximal pulmonary vessels 
and aortic arch. He was rather young considering the median 
age (51 years old) of the literally reviewed cases. He showed 
metastatic brain lesion and staged as Masaoka stage IV. Tumor 
tissue underwent IHC staining for CD5, TTF1, and Napsin A. 
TTF1 and Napsin A are distinguishable point of our case from 
previously reported cases. TTF1 and Napsin A are well known 
IHC markers to differentiate primary lung adenocarcinoma 
D
A
B
C
Figure 3. Radiographic images after the 
concurrent chemoradiation therapy. 
The size of the tumor decreased to 2.85 
cm in diameter on the chest CT scan 
taken at the 1-month follow-up visit (A) 
and successfully maintained the size at 
the 3-month follow-up visit, indicating 
stable disease (B). Brain MRI taken at 
the 1-month follow-up showed an al-
most resolved focal metastatic brain le-
sion on the left frontal lobe (C) and well-
maintained resolved lesion on the brain 
MRI taken at the 3-month follow-up visit 
(D).
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from squamous carcinoma13. Napsin A is reported to present 
100% specificity and 81% sensitivity to detect adenocarcino-
ma which negative predictive value is 83%. TTF1 showed 98% 
specificity and 70% sensitivity and 79% of negative predictive 
value. Those scores are reported as most valuable among the 
other similar IHC markers13.
He underwent four cycles of cisplatin and etoposide with 
concurrent radiotherapy to the lesion and salvage radiothera-
py to the brain resulted in favorable clinical outcome. Follow-
up chest CT and brain MRI at 1 month and 3 months after the 
treatment showed stable disease status without symptoms. 
There is no standard treatment for inoperable primary thymic 
adenocarcinoma. For the operable thymic carcinoma which 
may include adenocarcinoma of the thymus origin, surgical 
resection with adjuvant radiotherapy and/or adjuvant cisplat-
in-based chemotherapy is recommended3. Although the sub-
types of the tumor were not the primary thymic adenocarci-
noma, seven inoperable thymoma or thymic carcinoma with 
extra-thoracic site lesions like supraclavicular lymph node 
metastasis treated with palliative chemotherapy for the initial 
treatment and concluded the presence of extrathoracic metas-
tasis and histologically diagnosed as a thymic carcinoma are 
significant factors for progression free survival (hazard ratio, 
6.62; 95% confidence interval, 1.19–24.17, p=0.004)14. In our 
case, we applied concurrent chemoradiation therapy to the 
primary thymic adenocarcinoma patient with extrathoracic 
metastasis like brain metastasis (masaoka stage IVb) showed 
favorable clinical outcome. 
Considering listed above, we conclude that it is reasonable 
underwent IHC staining for CD5, TTF1, and Napsin A for the 
cases suggesting primary thymic adenocarcinoma on the 
H&E staining. Furthermore, when the case is inoprerable pri-
mary thymic adenocarcinoma with extrathoracic metastasis, 
concurrent chemoradiation therapy with focal salvage radio-
therapy could be an efficient treatment option for favorable 
clinical outcome.
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